Company name : KYORIN Holdings, Inc.
Representative Director, President : Minoru Hogawa
Securities Code : 4569, TSE 1st Sec.

®

NHI Drug Price Listing of PENTASA Granules 94%,a treatment for Ulcerative Colitis and Crohn's Disease
TOKYO, Japan (December 11, 2015) ― Kyorin Pharmaceutical Co., Ltd. (“Kyorin”) (Head office:Chiyoda-ku,Tokyo, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc.,
announced today that Ulcerative Colitis and Crohn's Disease treatment drug of “PENTASA® Granules 94%”has been listed on the National Health Insurance (NHI) drug price. In addition, the launch of the product isscheduled for release in December. The product received marketing authorization from the Ministry of Health,Labour and Welfare in August 2015.
Kyorin Pharmaceutical has been working to develop novel dosage forms and to gain approval of novel
administration and dosage to satisfy the therapeutic needs of patients with inflammatory bowel diseases(ulcerative colitis and Crohn’s disease). To date, the company has released Pentasa® Tablets 250 mg,Pentasa® Tablets 500 mg, Pentasa® Enema 1 g, and Pentasa® Suppositories 1 g.
Pentasa® Granules 94% is a granular agent developed for patients who have difficulty taking pills because of
the large size of the oral mesalazine tablet or the need to ingest multiple pills. With substantially decreased
dosage, achieved by increasing the mesalazine content to 94% using the company’s own technology, thisagent will enable patients to take oral medication in one dose with a single stick (a maximum of 2000 mg ofmesalazine), when a large quantity of mesalazine is required with each dose. We believe these advantages
will encourage greater therapeutic compliance.
Kyorin Pharmaceutical has added Pentasa®Granules 94% to its existing lineup of dosage forms. Movingforward, it will continue to provide the latest information as it works to support the treatment of patients with
inflammatory bowel disease.
The sales of the drug is factored in consolidated forecast for the fiscal year ending March 31 2016.

< Product photo >< Product information >®

1．Brand namePENTASA Granules 94%

2．Active ingredient

Mesalazine

3．Indications
4．Dosage andadministration

Ulcerative colitis (excluding severe cases), and Crohn’s disease
Ulcerative colitis:
The usual oral dosage of this product in adults is 1,500 mg of mesalazine daily in three divided
doses after meals, in the remission stage, however, this product may be administered once
daily, as required. The dosage may be adjusted according to patients’ ages and symptoms, withthe upper limit of 2,250 mg daily.

In the active stage, however, this product may beadministered in a daily dose of 4,000 mg in two divided portions, as required. The usual oral
dosage of this product in children is 30 to 60 mg/kg of mesalazine daily in three divided doses
after meals. The dosage may be adjusted according to patients’ ages and symptoms, with theupper limit of 2,250 mg daily.
Crohn’s disease:
The usual oral dosage of this product in adults is 1,500 to 3,000 mg of mesalazine daily in three
divided doses after meals. The dosage may be reduced according to patients’ ages andsymptoms. The usual oral dosage of this product in children is 40 to 60 mg/kg of mesalazine
daily in three divided doses after meals. The dosage may be adjusted according to patients’ ages
and symptoms.
5.NHI Price :94%1g

6．Packaging

Boxes of 100 packets

7.Date of Drug Price¥164.90(250mg※×100 packets)(500mg※×100 packets)(1000mg※×100 packets)
December 11, 2015(2000mg※×100 packets)

Listing :8.Date of initial
marketing in Japan

By the end of December, 2015

※Mesalazine